Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by next generation sequencing by Rechsteiner, Markus et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Modelling of a genetically diverse evolution of Systemic Mastocytosis with
Chronic Myelomonocytic Leukemia (SM-CMML) by next generation
sequencing
Rechsteiner, Markus; Müller, Rouven; Reineke, Tanja; Goede, Jeroen; Bohnert, Annette; Zhong, Qing;
Manz, Markus G; Moch, Holger; Wild, Peter J; Zimmermann, Dieter R; Tinguely, Marianne
Abstract: BACKGROUND Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) pro-
liferation, rarely associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KIT
(D816V) is regarded as driver-mutation in SM-AHNMD. METHODS DNA isolated from peripheral
blood (PB) of an SM-CMML patient was investigated with targeted next generation sequencing. Vari-
ants were verified by Sanger sequencing and further characterized in the SM part of the bone marrow
trephine (BMT), normal tissue, and FACS sorted PB cell subpopulations. FINDINGS Low coverage
deep-sequencing (mean 10x) on a GS 454 Junior revealed two as yet unreported SNVs (CBFA2T3 and
CLTCL1), both germ-line mutations. High coverage (mean 1674x) targeted re-sequencing on an Ion Pro-
ton revealed 177 variants in coding regions. Excluding SNPs, the final list comprised 11 variants. Among
these, TET2 (p.Thr1027fs, p.Cys1263Ser) and RUNX1 (p.Asn109Ser) were identified in in the peripheral
blood and the SM part of BMT, but not in normal tissue. Furthermore, Sanger sequencing of PB cells
revealed similar signal intensities for both TET2 mutations in FACS sorted CD34+ precursor cells and
CD16+ granulocytes comparable to signals in the SM part of BMT. In contrast, RUNX1 exhibited a
double intensity in CD34+ cells compared to the SM part of BMT and a homozygous variant signal in
granulocytes. Both TET2 and RUNX1 mutations were not detectable in B- and T-cells. CONCLUSION
We present a heterozygous triple-mutation pattern (KIT, TET2, RUNX1) in mast cells (SM disease
part) with additional LOH of RUNX1 in granulocytes (CMML disease part). These identified mutations
allow a more detailed insight into a multistep pathogenesis which suggests a common tumor progenitor
in SM-CMML.
DOI: 10.1186/2162-3619-3-18
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-97735
Published Version
 
 
Originally published at:
Rechsteiner, Markus; Müller, Rouven; Reineke, Tanja; Goede, Jeroen; Bohnert, Annette; Zhong, Qing;
Manz, Markus G; Moch, Holger; Wild, Peter J; Zimmermann, Dieter R; Tinguely, Marianne (2014).
Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic
Leukemia (SM-CMML) by next generation sequencing. Experimental Hematology Oncology, 3:18. DOI:
10.1186/2162-3619-3-18
2
RAPID COMMUNICATION Open Access
Modelling of a genetically diverse evolution
of Systemic Mastocytosis with Chronic
Myelomonocytic Leukemia (SM-CMML) by Next
Generation Sequencing
Markus Rechsteiner1, Rouven Müller2, Tanja Reineke1, Jeroen Goede2, Annette Bohnert1, Qing Zhong1,
Markus G Manz2, Holger Moch1, Peter J Wild1, Dieter R Zimmermann1 and Marianne Tinguely1,3*
Abstract
Background: Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) proliferation, rarely associated
with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KITD816V is regarded as driver-mutation in
SM-AHNMD.
Methods: DNA isolated from peripheral blood (PB) of an SM-CMML patient was investigated with targeted next
generation sequencing. Variants were verified by Sanger sequencing and further characterized in the SM part of the
bone marrow trephine (BMT), normal tissue, and FACS sorted PB cell subpopulations.
Findings: Low coverage deep-sequencing (mean 10x) on a GS 454 Junior revealed two as yet unreported SNVs
(CBFA2T3 and CLTCL1), both germ-line mutations. High coverage (mean 1674x) targeted re-sequencing on an Ion
Proton revealed 177 variants in coding regions. Excluding SNPs, the final list comprised 11 variants. Among these, TET2
(p.Thr1027fs, p.Cys1263Ser) and RUNX1 (p.Asn109Ser) were identified in in the peripheral blood and the SM part of
BMT, but not in normal tissue. Furthermore, Sanger sequencing of PB cells revealed similar signal intensities for both
TET2 mutations in FACS sorted CD34+ precursor cells and CD16+ granulocytes comparable to signals in the SM part of
BMT. In contrast, RUNX1 exhibited a double intensity in CD34+ cells compared to the SM part of BMT and a
homozygous variant signal in granulocytes. Both TET2 and RUNX1 mutations were not detectable in B- and T-cells.
Conclusion: We present a heterozygous triple-mutation pattern (KIT, TET2, RUNX1) in mast cells (SM disease part) with
additional LOH of RUNX1 in granulocytes (CMML disease part). These identified mutations allow a more detailed insight
into a multistep pathogenesis which suggests a common tumor progenitor in SM-CMML.
Keywords: Chronic myelomonocytic leukemia, Systemic mastocytosis, SM-CMML, Next Generation Sequencing, c-KIT
mutation, TET-2 mutation, RUNX1 mutation
Background
Systemic mastocytosis (SM) rarely occurs in combination
with so called “associated clonal haematological non-mast
cell lineage disease” (AHNMD) [1-5]. In most instances,
the AHNMD component is of myeloid origin, including
acute myeloid leukemia (AML), chronic myelomonocytic
leukemia (CMML) or primary myelofibrosis (PMF)
[1,6-8]. Recently, KITD816V mutations were identified in
both disease components of SM-AHNMD with the high-
est frequency in SM-CMML [9], suggesting a common
precursor.
Methods and findings
We report on a 73 year old male patient who was ini-
tially diagnosed with CMML. Untreated for three years,
extended investigations for disease progression showed a
normal karyotype and neither a JAK-2 mutation nor a
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BCR-ABL fusion gene. Due to abnormal BM mast cell
infiltrates the patient met the WHO 08 [1] criteria for
SM-CMML with proven KITD816V mutation in different
cell subpopulations as detailed in (Figure 1A-D). The pa-
tient died of disease under treatment with azacitidin
(vidaza®) four months after this diagnosis. Autopsy find-
ings showed additionally to the bone marrow involve-
ment widespread disease in different extramedullary
haematopoietic and visceral organs. There was no trans-
formation into acute leukemia.
We applied a cancer gene panel containing 427 genes,
custom-designed to include all exons of these genes on a
solid capture array by NimbleGen (Roche). Captured tar-
gets (Additional file 1: Table S1) were deep-sequenced
on a GS 454-Junior (Roche) revealing 1033 gene variants
with a mean coverage of 10-fold. The analysis with the GS
Reference Mapper software v.2.5 (Roche; default settings
and hg19 as reference genome) identified, next to the suc-
cessfully verified KITD816V mutation, sixty-four (6%) variants
in the coding region of 42 genes (Additional file 2: Table
S2). Of the 64 variants, 61 (95%) were single nucleotide
polymorphisms. The remaining were two as yet unreported
SNVs (CBFA2T3 and CLTCL1) and one 1-bp deletion
(BLM; COSM252959). All three mutations were confirmed
by Sanger sequencing (Genetic Analyzer 3130xl (Applied
Biosystems); [10]) using DNA from PB, the SM part of
BMT and normal tissue, meeting the criteria for germ-line
mutations (representative sequences in Figure 2A). Since,
however, the assumed 1-bp deletion of BLM at
AA515del1 – Asn515fs*16 could be identified in a non-
tumoral human embryonic kidney cell line (HEK293T),
we interpreted this aberration as a PCR/sequencing
artefact associated with a mononucleotide repeat at
this site. This finding was additionally confirmed by sub-
cloning of the PCR-product in a bacterial expression vector
and sequencing with different primer sets (Additional file 3:
Figure S1). Interestingly, previous reports describe exactly
the same deletion in gastrointestinal cancer and in T-ALL
cell lines [11,12].
To achieve a higher resolution we performed a high
coverage targeted re-sequencing with identical blood
derived DNA using the Ion AmpliSeq™ Comprehensive
Cancer Panel comprising all exons of 409 known cancer
genes (Life Technologies). Forty ng DNA was used as
input and the target regions were 13-fold PCR amplified.
After ligation of Torrent specific adapters, the amplicons
were subjected to clonal expansion on spheres using the
Ion One Touch 2 system (Life Technologies). Subse-
quently, the amplicons were dispersed on a PI chip and
sequenced on the Ion Proton platform [13]. Mean cover-
age was 1674-fold whereas more than 93% of the ampli-
cons were covered at least 100-fold and more than 81% at
least 500-fold allowing sensitive variant detection. Align-
ment (hg19), local re-alignment (2-fold), and probabilistic
variant detection (90% probability and 10-fold coverage)
were performed using CLC Genomics Workbench version
5.5. Additional filtering resulted in variants with following
characteristics: i) non-synonymous variants and INDELs
resulting in frame-shifts, ii) phred-score > = 20 and variant
coverage > = 50x, and iii) forward/reverse read ratio > =
0.25. These filter criteria resulted in identifying 177 vari-
ants (Additional file 4: Table S3). From these, 144 were
present in the 1000 Genome database and dbSNP and
were therefore excluded in the following analysis. Under
additional more stringent filtering criteria for 1-bp INDELs
in homopolymeric regions (CLC default settings for 454/
Ion) a final list of 11 variants emerged (Additional file 5:
Table S4) including KITD816V. Interestingly, variants of two
genes previously described in SM-AHNMD [14] TET2
(p.Thr1027fs, p.Cys1263Ser) and RUNX1 (p.Asn109Ser)
were detected. Although detectable by the 454-Junior,
their coverage was too low to be called by the GS Refer-
ence Mapper. Of note, 44 variants of the 64 variants
identified by the 454-Junior/GS Reference Mapper plat-
form lay in target regions of the CCP (Additional file 2:
Table S2). From these, 35 were verified by the Ion Tor-
rent/CLC platform, one was differently aligned, and eight
were not detected.
Thus, the variants in TET2 and RUNX1 represented
most probably true positive calls potentially involved in
SM-CMML pathogenesis. Although, they have not yet
been reported in the Cosmic database, the mutations
highly likely influence the protein function: i) the frame-
shift mutation in TET2 occurring in front of the two
conserved regions of TET2 (1104–1478, 1845–2002)
and the SNV lying within the first region [15], ii) the
mutation in RUNX1 located in the RUNT domain which
is responsible for proper DNA binding and heterodimer-
ization [16].
The 2-bp insertion (p.Thr1027fs) and the SNV (p.
Cys1263Ser) in TET2, and the SNV (p.Asn109Ser) in
RUNX1 were confirmed in PB and the SM part of BMT
(Figure 2B). Very low signals of the variants were de-
tected in normal tissue, most probably due to infiltrating
mast cells. Whereas no signals were found in B- and T-
lymphocytes, similar signal intensities for both TET2
mutations were seen in CD34+ precursor cells and
CD16+ granulocytes comparable to the signals in the
SM part of BMT (Figure 2C). In contrast, RUNX1 exhib-
ited a double intensity of the variant in CD34+ cells
compared to the SM part of BMT and a homozygous
variant signal in granulocytes.
Inasmuch the SNPs and seven variants identified
(Additional file 5: Table S4) are implicated in the disease
development needs to be confirmed. Importantly how-
ever, we present an in-depth analysis of the sub-clonal
relation of SM-CMML which reveals essential concomi-
tant key mutations in KIT, TET2, and RUNX1 in the
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Rechsteiner et al. Experimental Hematology & Oncology 2014, 3:18 Page 3 of 6
http://www.ehoonline.org/content/3/1/18
emergence of different disease compartments. Since the
mutant allelic fraction in the blood of KIT (0.44), TET2
(0.45, 0.44), and RUNX1 (0.53) assessed by NGS (Proton
platform) were in a similar range (Additional file 5:
Table S4), we assume that these mutations belong to the
same CD34+ sub-clonal cell population. This is sup-
ported by the fact that the electropherograms of the
Sanger sequencing exhibited the same intensities for KIT
and TET2 mutations in blood and the SM-area as well
as in the sorted CD34+ and granulocytic cell fraction
(Figure 2). Additionally, RUNX1 mutant signals assessed
by Sanger sequencing were highest in the granulocytic
cell fraction and balanced with wild-type in the SM-area
(purity 90%) which implies that an additional LOH of
RUNX1 occured in a CD34+ mast cells precursor. This
is as well reflected by the fact that the mutant allelic
fraction of RUNX1 (0.53) in the blood assessed by NGS
(Proton platform) was increased by 0.09 in comparison
to the other three SNVs (mean mutant allelic fraction
KIT, 2x TET2: 0.44). Since the KIT (CD117) protein is
expressed in the SM, but not in the CMML compart-
ment (Figure 1) ascribes the KITD816V mutation a pivotal
role in the disease initiation, particularly of the SM frac-
tion. Whereas TET2 and RUNX1 were necessary sequen-
tial mutations for progression to overt SM, homozygous
loss of wild-type RUNX1 seemingly was the driver muta-
tion enabling a clonal expansion of the CMML lineage
as suggested by our disease model (Figure 3). This fur-
ther underlines the concept of common tumour pro-
genitor cells leading to a spectrum of the same disease
rather than two different ones as the term SM-AHNMD
evokes. The presence of RUNX1 and TET2 mutations in
(See figure on previous page.)
Figure 1 Assessment of the KITD816V mutation on the bone marrow trephine. A upper line: HE stain of the bone marrow trephine showing
both, CMML and SM part in distinct areas in this patient (left). A CD117 immunostain (right) highlights the mast cells in the SM compartment,
however cells within the CMML compartment are negative. Lower line: HE control before and after punching out the SM area (containing around
90% of MC in the CD117 staining) submitted to PCR and Sanger Sequencing. B Forward and reverse sequences indicating the KITD816V mutation
of microdissected SM area of the bone marrow trephine. C FACS sorted cells as indicated with a purity of around 90% for CD34+ stem cells and
granulocytes. D Shows the sequencing results of the PCR amplification product for KITD816V, and forward strands for isolated cell-subpopulations
respectively.
Figure 2 Verification of identified variants by Sanger sequencing. A: Representative sequences of CBFA2T3, CLTCL1, and BLM using DNA
derived from the SM part of BMT, PB, and the SM part of BMT, respectively. B: Sequencing of TET2 and RUNX1 using DNA derived from PB, the
SM part of BMT, and normal tissue. C: Sequencing of TET2 and RUNX1 using DNA derived from FACS sorted PB cell populations.
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mature granulocytes and in MC of the BMT in our
study is quite novel, since so far only one recent study
showed concomitant mutations of KIT and TET2 in
mast cells and granulocytes in SM-AHNMD [14]. The
increased number of driving-mutations could explain
the rapid clinical progression in our patient and is in line
with the previous study, advocating additional molecular
aberrations a prognostic role [14].
In summary, the current SM-CMML derived from the
same mutated tumour progenitor cells (KIT SNV, TET2
frame-shift, TET2 SNV, RUNX1 SNV) which acquired
additional mutations (i.e. RUNX1 wild-type loss) in dif-
ferent sub-clones as hypothesised in our model to finally
manifest in the pathological state of SM-CMML.
Consent
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Figure 3 Hypothetical disease model of SM-CMML pathogenesis.
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